Patent EP0511152A2 successfully refreshed from Google Patents.
EP0511152A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Quinoxaline compounds, their preparation and use
Assignee: Novo Nordisk AS
•
Filing: 1992-04-06
•
Granted: —
•
Expires: 2012-04-06
Abstract
Abstract Quinoxaline compounds having the formula I wherein R¹ is H, NO₂, CN, CF₃ or halogen, R² and R³ independently are H, CN, CF₃, halogen, C(NOH)C₁₋₆- alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted, or NR⁵R⁶, wherein R⁵, R⁶ independently are H, C₃₋₆-cycloalkyl, C₁₋₆-alkyl-, optionally substituted, compositions thereof and methods of preparing the compounds are described. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.
Inventors
- 👤 Poul Jakobsen
- 👤 Flemming Elmelund Nielsen
- 👤 Lars Naerum
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 16:20
CPC Classifications
C; C07; C07D; C07D241/00; C07D241/36; C07D241/38; C07D403/00; C07D403/02; C07D403/12
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
57 words
Quinoxaline compounds having the formula I wherein R¹ is hydrogen, NO₂, CN, CF₃ or halogen, R² and R³ independently are hydrogen, CN, CF₃, halogen, C(NOH)C₁₋₆-alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted with CONH₂, or NR⁵R⁶, wherein R⁵, R⁶ independently are hydrogen, C₃₋₆-cycloalkyl, C₁₋₆-alkyl optionally substituted with CONH₂ or 2-oxo-pyrrolidinyl, or pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
57 words
Quinoxaline compounds having the formula I wherein R¹ is hydrogen, NO₂, CN, CF₃ or halogen, R² and R³ independently are hydrogen, CN, CF₃, halogen, C(NOH)C₁₋₆-alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted with CONH₂, or NR⁵R⁶, wherein R⁵, R⁶ independently are hydrogen, C₃₋₆-cycloalkyl, C₁₋₆-alkyl optionally substituted with CONH₂ or 2-oxo-pyrrolidinyl, or pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
9 words
A compound according to claim 1 which is 6-nitro-8-sulfamoylbenzo-[f]quinoxaline-2,3(1H,4H)-dione.
Claim 4
Dependent Claim
9 words
A compound according to claim 1 which is 8-(carbamoyl-methyl)sulfonyl-6-nitrobenzo[f]quinoxaline-2,3(1H,4H)-dione.
Claim 5
Dependent Claim
9 words
Compounds according to claim 1 which is 6-cyano-8-sulfamoylbenzo[f]quinoxaline-2,3(1H,4H)-dione, 8-carbamoyl-6-nitrobenzo[f]quinoxaline-2,3(1H,4H)-dione.
Claim 6
Dependent Claim
26 words
A pharmaceutical composition comprising as active component a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
Claim 7
Dependent Claim
22 words
A pharmaceutical composition according to claim 5 in the form of a dosage unit containing about 10-200 mg of the active compound.
Claim 8
Dependent Claim
43 words
A pharmaceutical composition suitable for use in the treatment of an indication related to hyperactivity of the excitatory neurotransmitters, which comprises as active component a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
Claim 9
Independent Claim
93 words
A method of treating an indication related to hyperactivity of the excitatory neurotransmitters in a subject in need thereof, which comprises the step of administering to the said subject a neurologically effective AMPA antagonistic amount of a compound having the formula I wherein R¹ is hydrogen, NO₂, CN, CF₃ or halogen, R² and R³ independently are hydrogen, CN, CF₃, halogen, C(NOH)C₁₋₆-alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted with CONH₂, or NR⁵R⁶, wherein R⁵, R⁶ independently are hydrogen, C₃₋₆-cycloalkyl, C₁₋₆-alkyl, optionally substituted with CONH₂ or 2-oxo-pyrrolidinyl, or pharmaceutically acceptable salts thereof.
Claim 10
Independent Claim
93 words
A method of treating an indication related to hyperactivity of the excitatory neurotransmitters in a subject in need thereof, which comprises the step of administering to the said subject a neurologically effective AMPA antagonistic amount of a compound having the formula I wherein R¹ is hydrogen, NO₂, CN, CF₃ or halogen, R² and R³ independently are hydrogen, CN, CF₃, halogen, C(NOH)C₁₋₆-alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted with CONH₂, or NR⁵R⁶, wherein R⁵, R⁶ independently are hydrogen, C₃₋₆-cycloalkyl, C₁₋₆-alkyl, optionally substituted with CONH₂ or 2-oxo-pyrrolidinyl, or pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
14 words
A method according to claim 8, wherein the indication is related to cerebral ischemia.
Claim 12
Dependent Claim
233 words
A method of preparing a compound according to claim 1, which comprises a) reacting a compound having the formula II wherein R¹, R² and R³ have the meanings defined above, with oxalate or a reactive derivative thereof to form a compound of formula I, or b) refluxing a compound having the formula III wherein R¹, R² and R³ have the meanings defined above and R⁷ is lower alkyl in a mineral acid, to form a compound of formula I, or c) nitrating a compound having the formula IV wherein at least one of R 1′ , R 2′ and R 3′ is hydrogen and the others are as defined for R¹, R² and R³ respectively, to form a compound of formula I, or d) reducing a compound having the formula V wherein at least one of R 1˝ , R 2˝ and R 3˝ is nitro and the others are as defined for R¹, R² and R³ respectively, to form a compound of formula I, wherein at least one of R¹, R² and R³ is amino, or e) reacting a compound having the formula VI wherein at least one of R 1‴ , R 2‴ and R 3‴ is N₂⁺ and the others are as defined for R¹, R² and R³ respectively, with potassium tetracyanonickelate to form a compound of formula I, wherein at least one of R¹, R² and R³ is CN.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.